Business
Pharming Group to report third quarter 2025 financial results and provide business update on November 6
Leiden, the Netherlands, October 23, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the third quarter 2025 and provide a business update on Thursday, November 6, 2025. Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CET/07:30 am ET. To participate in the conference call or to watch the live webcast, please register in advance using
About this update from Pharming Group Nv
Leiden, the Netherlands, October 23, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) confirms that it will report its preliminary (unaudited) financial results for the third quarter 2025 and provide a business update on Thursday, November 6, 2025. Management will host a conference call and webcast for analysts and investors on the same day at 13:30 CET/07:30 am ET. To participate in the conference call or to watch the live webcast, please register in advance using the links below. Conference call registration: https://register-conf.media-server.com/register/BI1b6a1a63294c427f91ab7b24a7c6484b Once registered, dial-in information and a unique PIN will be provided, allowing access to the call. Please note, the Company will only take questions from dial-in attendees. Webcast registration: https://edge.media-server.com/mmc/p/vb724dzx The webcast will also be accessible on the Pharming website at Investors/Financial Documents , and a replay will be available shortly after the event. About Pharming Group N.V. Pharming Group N.V. (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. We are developing and commercializing a portfolio of innovative medicines, including small molecules and biologics. Pharming is headquartered in Leiden, the Netherlands, with a significant proportion of its employees based in the U.S. For more information, visit www.pharming.com and find us on LinkedIn . For further public information, contact: Pharming Group, Leiden, the Netherlands Michael Levitan, VP Investor Relations & Corporate Communications T: +1 (908) 705 1696 E: [email protected] LifeSpring Life Sciences Communication, Amsterdam, the Netherlands Leon Melens T: +31 6 53 81 64 27 E: [email protected] Attachment